Log In
BCIQ
Print this Print this
 

CXL-1427

  Manage Alerts
Collapse Summary General Information
Company Cardioxyl Pharmaceuticals Inc.
DescriptionSecond-generation prodrug of nitroxyl (HNO)
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHeart failure
Indication DetailsTreat acute decompensated heart failure (ADHF)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2,100.0M

$300.0M

$1,800.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/08/2015

$2,100.0M

$300.0M

$1,800.0M

Get a free BioCentury trial today